Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs NIO Inc. (NIO) Price & Performance

Abeona Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs NIO Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.36 (market cap $421.19M), while NIO Inc. trades at $4.58 (market cap $11.59B). The key difference: NIO Inc. is far larger — about 27.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.

ABEONIO
Market Cap
$421.19M$11.59B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$7.89
52-Week Low
$4.17$4.44
Enterprise Value
$276.10M$10.82B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

NIO Inc.

NIO trades at $4.82, up 1.69% today, showing recent volatility amid mixed market signals. The company reported July 2026 deliveries growth and has beaten earnings expectations for three consecutive quarters, though it remains unprofitable with a net income margin of -9.09%. Technical indicators show neutral momentum with RSI at neutral levels, while analyst sentiment leans bullish with 54% buy ratings.

NIO presents a high-risk growth opportunity with improving revenue trends but persistent losses. The stock offers potential upside if profitability improves, but faces significant execution risks in the competitive EV market. Investors should weigh strong delivery growth against cash burn and negative equity returns before considering position entry.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About NIO Inc.

NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.

Read more on NIO